Raras
Buscar doenças, sintomas, genes...
Adenoma hipofisário não-secretor
ORPHA:91349CID-10 · D35.2CID-11 · 2F37.0DOENÇA RARA

Um tumor na hipófise que pode ou não produzir hormônios, e que não provoca nenhum sintoma relacionado a alterações hormonais.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Um tumor na hipófise que pode ou não produzir hormônios, e que não provoca nenhum sintoma relacionado a alterações hormonais.

Pesquisas ativas
3 ensaios
18 total registrados no ClinicalTrials.gov
Publicações científicas
960 artigos
Último publicado: 2026 Apr 6

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
Adolescent
+ adult, childhood
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D35.2
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
16 sintomas
🫃
Digestivo
4 sintomas
👁️
Olhos
4 sintomas
🫘
Rins
3 sintomas
🧠
Neurológico
2 sintomas
🧬
Pele e cabelo
1 sintomas

+ 26 sintomas em outras categorias

Características mais comuns

90%prev.
Adenoma hipofisário
Muito frequente (99-80%)
55%prev.
Quantidade anormal de cabelo
Frequente (79-30%)
55%prev.
Palidez
Frequente (79-30%)
55%prev.
Hipotireoidismo hipofisário
Frequente (79-30%)
55%prev.
Morfologia anormal da glândula pituitária
Frequente (79-30%)
55%prev.
Impotência
Frequente (79-30%)
58sintomas
Muito frequente (1)
Frequente (36)
Ocasional (21)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 58 características clínicas mais associadas, ordenadas por frequência.

Adenoma hipofisárioPituitary adenoma
Muito frequente (99-80%)90%
Quantidade anormal de cabeloAbnormal hair quantity
Frequente (79-30%)55%
PalidezPallor
Frequente (79-30%)55%
Hipotireoidismo hipofisárioPituitary hypothyroidism
Frequente (79-30%)55%
Morfologia anormal da glândula pituitáriaAbnormality of the pituitary gland
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico960PubMed
Últimos 10 anos200publicações
Pico202131 papers
Linha do tempo
2026Hoje · 2026🧪 1998Primeiro ensaio clínico📈 2021Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

2 genes identificados com associação a esta condição. Padrão de herança: Not applicable.

MEN1MeninCandidate gene tested inAltamente restrito
FUNÇÃO

Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (4)
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcriptionDeactivation of the beta-catenin transactivating complexFormation of the beta-catenin:TCF transactivating complexFormation of WDR5-containing histone-modifying complexes
MECANISMO DE DOENÇA

Familial multiple endocrine neoplasia type I

Autosomal dominant disorder characterized by tumors of the parathyroid glands, gastro-intestinal endocrine tissue, the anterior pituitary and other tissues. Cutaneous lesions and nervous-tissue tumors can exist. Prognosis in MEN1 patients is related to hormonal hypersecretion by tumors, such as hypergastrinemia causing severe peptic ulcer disease (Zollinger-Ellison syndrome, ZES), primary hyperparathyroidism, and acute forms of hyperinsulinemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
45.1 TPM
Tireoide
43.2 TPM
Cérebro - Hemisfério cerebelar
40.2 TPM
Fibroblastos
37.9 TPM
Baço
35.0 TPM
OUTRAS DOENÇAS (7)
multiple endocrine neoplasia type 1pituitary gigantismnull pituitary adenomaprolactin-producing pituitary gland adenoma
HGNC:7010UniProt:O00255
AIPSmall ribosomal subunit protein bS22, mitochondrialCandidate gene tested inModerado
FUNÇÃO

May act as a negative regulator of Aurora-A kinase, by down-regulation through proteasome-dependent degradation

LOCALIZAÇÃO

Mitochondrion matrixNucleus

VIAS BIOLÓGICAS (2)
Aryl hydrocarbon receptor signallingGene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
OUTRAS DOENÇAS (7)
growth hormone secreting pituitary adenoma 1familial isolated pituitary adenomapituitary gigantismsilent pituitary adenoma
HGNC:358UniProt:Q9NWT8

Variantes genéticas (ClinVar)

1,066 variantes patogênicas registradas no ClinVar.

🧬 MEN1: NM_001370259.2(MEN1):c.1186-1G>C ()
🧬 MEN1: NM_001370259.2(MEN1):c.767T>G (p.Leu256Arg) ()
🧬 MEN1: NM_001370259.2(MEN1):c.1009G>A (p.Ala337Thr) ()
🧬 MEN1: NM_001370259.2(MEN1):c.478dup (p.Ala160fs) ()
🧬 MEN1: NM_001370259.2(MEN1):c.361dup (p.Val121fs) ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado1
3Fase 31
2Fase 24
·Pré-clínico5
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 11 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Adenoma hipofisário não-secretor

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

3 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

18 ensaios clínicos encontrados, 3 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
231 papers (10 anos)
#1

Oridonin regulates pituitary-derived folliculostellate cells apoptosis via the p38 MAPK/p53 signalling pathway.

European journal of pharmacology2026 Mar 28

Treatment of non-functioning pituitary adenoma remains challenging owing to a lack of effective pharmacological therapies. A previous study has shown that oridonin (ORI) induces apoptosis in pituitary-derived folliculostellate (PDFS) cells; therefore, this study further investigated the molecular mechanisms by which ORI-mediated regulates apoptosis in PDFS cells. To confirm the regulatory role of the p38 mitogen-activated protein kinase (MAPK)/p53 signalling pathway, molecular docking and the p38 MAPK inhibitor SB202190 were used to evaluate pathway modulation. Effects on cell viability, migration, invasion, and apoptosis were evaluated using Calcein-AM/Propidium Iodide (PI) double staining, Transwell migration and invasion assays, and Western blot analysis. To further assess the in vivo effects of ORI, a subcutaneous xenograft model in nude mice was established, and ORI was administered at 5 and 10 mg/kg to assess therapeutic efficacy and safety. Safety was evaluated by analysing histopathological changes in major organs using haematoxylin-eosin (H&E) staining. Western blot analysis of tumour tissues was conducted to assess activation of the p38 MAPK/p53 pathway and the expression of apoptosis-related proteins. Molecular docking and Western blot assays confirmed that ORI binds to p38 protein with an affinity of -7.3 kcal/mol, markedly increasing p38 phosphorylation and p53 expression. The p38 MAPK inhibitor SB202190 reversed ORI-induced effects on cell death, cell migration and invasion, and apoptosis, highlighting the critical role of the p38 MAPK/p53 pathway. ORI effectively suppressed subcutaneous tumour growth in nude mice without notable toxicity while upregulating apoptosis-related proteins Bax and cleaved caspase-3 and downregulating Bcl-2 through activation of the p38 MAPK/p53 pathway.

#2

Sex-related differences in healthcare utilization and costs among patients with pituitary adenomas.

Pituitary2026 Feb 07

To systematically summarize and evaluate the current evidence regarding sex-based differences in healthcare utilization (HCRU), direct costs, and indirect socioeconomic burden in patients with pituitary adenomas. A systematic literature search of PubMed, EMBASE, and Web of Science identified studies reporting HCRU and/or cost data with sex-stratified analyses. Studies focusing on drug-specific cost-effectiveness, case reports, and scenario-based models were excluded. Eight studies met the inclusion criteria, including non-functioning pituitary adenoma, prolactinoma, acromegaly, Cushing's disease (CD), and perioperative pituitary tumor cohorts from Europe and the United States. Findings were synthesized narratively due to methodological heterogeneity and the scarcity of sex-specific cost estimates. Total and surgical costs did not differ between men and women across most settings in Europe. Only one U.S. acromegaly cohort showed lower adjusted annual costs in women, and one Chinese perioperative patient cohort reported lower inpatient charges among women. In contrast, sex-based differences in HCRU were consistent and clinically relevant: women with acromegaly demonstrated longer diagnostic delays, more pre-diagnostic visits, higher specialist engagement, and more treatment modifications. Perioperatively, sex was not a predictor of length of stay or cost, but several cohorts reported higher rates of cerebrospinal fluid leak, arginine-vasopressin deficiency, and late hyponatremia in women. The most pronounced disparity was observed in indirect socioeconomic burden, with women more frequently experiencing reduced work capacity, early retirement, psychosocial distress, and poorer quality-of-life in acromegaly and CD. Although sex-based differences in overall healthcare costs are limited, women face a disproportionately complex and burdensome care trajectory. Standardized, value-based care pathways may help mitigate these disparities, underscoring the need for prospective, sex-stratified studies.

#3

Sex and Age Differences in Transcription Factor and Hormonal Immunostaining in Patients With Nonfunctioning Pituitary Adenomas.

Operative neurosurgery (Hagerstown, Md.)2026 Jan 15

Nonfunctioning pituitary adenomas (NFPAs) have historically been characterized histologically based on hormonal immunostaining. The 2017 World Health Organization guidelines for pituitary neuroendocrine tumors further delineated NFPA classification based on biologically relevant transcription factors (TFs), including T-PIT, PIT-1, and steroidogenic factor 1 (SF-1). We sought to evaluate differences in NFPA immunohistochemistry (IHC) associated with biological sex and age according to new TF immunostaining criteria. A retrospective review of data from a single institution was conducted to identify patients who had undergone NFPA resection from 2012 to 2023. Patients grouped based on their biological sex and then further divided into age categories. Univariable statistics were used to identify associations between patient demographics and NFPA IHC. A total of 416 patients were included in the IHC-hormone analysis, and 154 patients were included in the IHC-TF analysis. Men were significantly less likely to have NFPAs with positive immunostaining for T-PIT (odds ratio [OR] = 0.15, 95% CI: 0.06-0.37) or adrenocorticotropic hormone (OR = 0.38, 95% CI: 0.22-0.64) and significantly more likely to have NFPAs stain positive for SF-1 (OR = 4.87, 95% CI: 2.24-10.6), follicle-stimulating hormone (FSH) (OR = 2.46, 95% CI: 1.64-3.69), luteinizing hormone (OR = 2.28, 95% CI: 1.26-4.13), thyroid-stimulating hormone (OR = 2.56, 95% CI: 1.05-6.26), or the alpha subunit (OR = 2.01, 95% CI: 1.36-2.97). Compared with the youngest age group, women in the oldest age group were more likely to have an NFPA stain positive for SF-1 (OR = 6.88, 95% CI: 1.86-25.4), FSH (OR = 2.32, 95% CI: 1.02-5.27), or the alpha subunit (OR = 2.14, 95% CI: 1.02-4.47). Similarly, men in the oldest age group were more likely to have an NFPA staining positive for FSH (OR = 4.16, 95% CI: 1.90-9.11) and the alpha subunit (OR = 2.36, 95% CI: 1.10-5.05); they were less likely to have positive immunostaining for adrenocorticotropic hormone (OR = 0.19, 95% CI: 0.04-0.79). There were no age-related differences in TF staining for male patients. This study demonstrates that sex and age are important demographic factors associated with immunostaining patterns and TF lineage subtypes for NFPAs. Underlying endocrine factors dictated by age and sex may represent a role in tumorigenesis or progression of NFPAs.

#4

Clinicopathological features and outcomes in non-functioning pituitary neuroendocrine tumors: a transcription factor-driven subtype analysis.

Journal of neuro-oncology2026 Jan 08

To assess the differences in clinicopathological features and outcomes of non-functioning pituitary neuroendocrine tumors (PitNETs) based on transcription factor expression. Clinical data were collected from patients diagnosed with non-functioning PitNETs at our hospital. Tumors were classified into transcription factor-based subgroups for comparison. Clinical characteristics were analyzed across these subgroups, and prognostic data were obtained through postoperative outpatient records and telephone follow-ups. A total of 409 patients were included, comprising 202 males (49.4%) and 207 females (50.6%). Of these, 245 (59.9%), 101 (24.7%), 39 (9.5%), and 24 (5.9%) patients were classified into the steroidogenic factor-1 (SF1), T-box transcription factor 19 (TPIT), POU class 1 homeobox 1 (PIT1), and no distinct lineage groups, respectively. The SF1 subgroup was associated with lipid metabolism disorders. The TPIT subgroup had the largest and most invasive tumors. Patients in the PIT1 and no distinct lineage groups were more likely to present with hyperprolactinemia and galactorrhea and showed a lower tendency to invade the cavernous sinus. The median follow-up duration was 801 days. The PIT1 and TPIT subgroups had shorter tumor-free survival, particularly the former. Further survival analysis revealed that patients with TPIT and PIT1 lineages had poorer prognoses. Transcription factor expression was associated with distinct clinical features and short-term outcomes. The PIT1 and TPIT lineages were linked to shorter tumor-free survival. Enhanced postoperative surveillance is recommended for these subgroups. These findings underscore the clinical and prognostic heterogeneity of non-functioning PitNETs.

#5

Impact of sex on mortality in patients with pituitary adenomas.

Pituitary2026 Feb 06

Publicações recentes

Ver todas no PubMed

📚 EuropePMC136 artigos no totalmostrando 198

2026

Oridonin regulates pituitary-derived folliculostellate cells apoptosis via the p38 MAPK/p53 signalling pathway.

European journal of pharmacology
2026

Sex-related differences in healthcare utilization and costs among patients with pituitary adenomas.

Pituitary
2026

Impact of sex on mortality in patients with pituitary adenomas.

Pituitary
2026

Sex and Age Differences in Transcription Factor and Hormonal Immunostaining in Patients With Nonfunctioning Pituitary Adenomas.

Operative neurosurgery (Hagerstown, Md.)
2026

Clinicopathological features and outcomes in non-functioning pituitary neuroendocrine tumors: a transcription factor-driven subtype analysis.

Journal of neuro-oncology
2025

Clinical, radiological, and pathological characteristics and long-term outcomes of silent corticotroph adenomas: a retrospective study.

BMC endocrine disorders
2025

Managing Atopic Dermatitis with Dupilumab in Special Populations: A Case Series Study.

Clinical, cosmetic and investigational dermatology
2025

Intensity-Modulated Proton Therapy for an Unresectable Giant Non-functioning Pituitary Adenoma: A Case Report and Literature Review.

Cureus
2025

Neurocognitive evaluation of patients with non-functioning pituitary adenoma.

Pituitary
2025

The association between sleep quality and cognitive function in patients with non-functioning pituitary adenoma.

Endocrine connections
2025

Autoimmune thyroid disease and pituitary adenoma in a female patient with 18p deletion syndrome: a case report and review of the literature.

BMC endocrine disorders
2025

Isolated syndrome of inappropriate antidiuresis (SIAD) after Transphenoidal surgery of a non-functioning pituitary adenoma: clinical case report.

Oxford medical case reports
2025

Anemia in Patients With Pituitary Adenomas: Prevalence and Correlation With Hypopituitarism.

Cureus
2025

Venous thromboembolism in patients with pituitary adenoma: UK multicentre cohort study.

European journal of endocrinology
2025

EEA for sellar chodrosarcomas: case series with literature review.

Chinese neurosurgical journal
2025

Baseline testosterone levels as a predictor of hypogonadism resolution in male patients with isolated hyperprolactinemia.

Pituitary
2025

PANOMEN-3 grading score is reliable in predicting pituitary adenoma behavior and prognosis: a single center cohort study.

Endocrine
2025

Headache as an indication for surgery in non-functioning pituitary adenoma and Rathke's cleft cyst: A systematic review.

Clinical neurology and neurosurgery
2025

Soluble alpha klotho-impact of biological variables and reference intervals for adults.

European journal of endocrinology
2025

Conservatively managed non-functioning pituitary macroadenomas-cohort study from the UK Non-functioning Pituitary Adenoma Consortium.

European journal of endocrinology
2025

Metformin induces apoptosis in pituitary-derived folliculostellate cells via the IL-6/ERK pathway.

Discover oncology
2025

Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre.

Pituitary
2025

Incidental High-Grade Sellar Solitary Fibrous Tumor Mimicking Non-Functioning Pituitary Adenoma: A Case Report and Literature Review.

The American journal of case reports
2025

Coexisting Non-functioning Pituitary Macroadenoma and Sellar-Suprasellar Lipoma: A Case Report and Literature Review.

Acta medica Philippina
2025

Etiology, presentation, and outcomes of hyperprolactinemia due to pituitary masses in children and adolescents.

Endocrine
2025

Person-centered support for patients with a pituitary tumor following surgery.

Endocrine connections
2024

Knosp and revised Knosp classifications predict non-functioning pituitary adenoma outcomes: a single tertiary center experience.

Journal of medicine and life
2024

A case of non-functioning pituitary adenoma with calcification.

Asian journal of surgery
2024

Quality of life in non-functioning pituitary adenoma: A systematic review.

Neurosurgical review
2025

Cognitive decline in Cushing's syndrome: A systematic review.

Journal of neuroendocrinology
2025

Comparative mortality in pituitary adenomas subtypes: a tertiary referral center study.

Endocrine
2024

Brain Arteriovenous Malformation Hemorrhage and Pituitary Adenoma in a COVID-19-Positive Patient.

Cureus
2024

Phenotypic presentation of MEN1 c.758delC (p.Ser253Cysfs *28) pathogenic variant: a case report.

Oxford medical case reports
2024

SZ-685C inhibits the growth of non-functioning pituitary adenoma by down-regulating miR-340-3p and inducing autophagy.

Heliyon
2024

Pituitary apoplexy: a comprehensive analysis of 93 cases across functioning and non-functioning pituitary adenomas from a single-center.

Pituitary
2024

Lanreotide versus placebo for tumour reduction in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment.

The Lancet regional health. Europe
2025

American Association of Neurological Surgeons/Congress of the Neurological Surgeons Section on Tumors Guidelines: Assessing Their Impact on Brain Tumor Clinical Practice.

Neurosurgery
2024

Differential expression of cancer-related lncRNAs in different subtypes of pituitary adenomas.

Pathology, research and practice
2024

Stem cell-associated transcription factors in non-functioning pituitary neuroendocrine tumours.

Free neuropathology
2024

Cardiovascular risk in patients with acromegaly vs. non-functioning pituitary adenoma following pituitary surgery: an active-comparator cohort study.

Pituitary
2024

High prevalence of morphometric vertebral fractures opportunistically detected on thoracic radiograms in patients with non-functioning pituitary adenoma.

Pituitary
2024

Giant Clinically Non-Functioning Pituitary Adenoma Presenting as New Onset Generalized Tonic‒Clonic Seizures: A Case Report.

International medical case reports journal
2024

Magnetic Resonance Imaging Features of the Sphenoid Sinus in Patients with Non-Functioning Pituitary Adenoma.

Medicina (Kaunas, Lithuania)
2024

Headache in patients with non-functioning pituitary adenoma before and after transsphenoidal surgery - a prospective study.

Pituitary
2024

Clinical and radiographic characteristics of patients with non-functioning pituitary adenomas categorized according to their serum prolactin concentration: novel predictors of postoperative transient diabetes insipidus following surgery.

Endocrine
2024

Medical and Surgical Approaches for a Non-functioning Pituitary Adenoma During Pregnancy.

Cureus
2024

Excess mortality in patients with non-functioning pituitary adenoma: a systematic review and meta-analysis.

Journal of endocrinological investigation
2024

Unique case of lymphocytic hypophysitis with normal pituitary hormone serology mimicking a non-functioning pituitary adenoma.

BMC endocrine disorders
2024

Perioperative growth hormone levels as an early predictor of new-onset secondary adrenal insufficiency following transsphenoidal pituitary tumor resection.

Asian journal of surgery
2023

The correlation among Claudin-9, Tyrosine kinase-2, and Signal transducers and activators of transcription-3 expressions in non-functioning pituitary adenoma and invasiveness.

Neuro endocrinology letters
2024

Cabergoline treatment for surgery-naïve non-functioning pituitary macroadenomas.

Pituitary
2023

Visual acuity in patients with non-functioning pituitary adenoma: Prognostic factors and long-term outcome after surgery.

Brain &amp; spine
2023

Skull Base Collision Tumors: Giant Non-functioning Pituitary Adenoma and Olfactory Groove Meningioma.

Cureus
2023

Non-functioning pituitary macroadenoma following surgery: long-term outcomes and development of an optimal follow-up strategy.

Frontiers in surgery
2023

Exploring endocrinological pitfalls in pituitary surgery in the elderly.

Heliyon
2023

Pituitary metastasis of hepatocellular carcinoma as the initial presentations: a case report and review of the literature.

Frontiers in oncology
2023

Pituitary function at presentation and following therapy in patients with non-functional pituitary macroadenomas: a single centre retrospective cohort study.

Endocrine
2023

Natural history of non-functioning pituitary microadenomas: results from the UK non-functioning pituitary adenoma consortium.

European journal of endocrinology
2023

Post-Operative Medium- and Long-Term Endocrine Outcomes in Patients with Non-Functioning Pituitary Adenomas-Machine Learning Analysis.

Cancers
2023

Expression of LINC00174 in different cancers: Review of the literature and bioinformatics analyses.

Pathology, research and practice
2023

Natural history of pituitary apoplexy: a long-term follow-up study.

Postgraduate medical journal
2023

Dysregulation of PVT1 and NEAT1 lncRNAs in pituitary adenomas.

Pathology, research and practice
2023

Sleep quality in patients with non-functioning pituitary adenoma: impact of replacement therapies with an emphasis on the time of hydrocortisone.

Pituitary
2023

Healthcare cost and survival in patients with non-functioning pituitary adenoma.

European journal of endocrinology
2023

Upregulation of MAPKAPK5-AS1, PXN-AS1 and URB1-AS1 lncRNAs in non-functioning pituitary adenoma.

Journal of cellular and molecular medicine
2025

Psychiatric disorders and anger in patients with controlled acromegaly.

Minerva endocrinology
2023

Low Bone Density and High Sclerostin in Non-Functioning Pituitary Adenoma.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
2023

Evaluation of preoperative visual pathway impairment in patients with non-functioning pituitary adenoma using diffusion tensor imaging coupled with optical coherence tomography.

Frontiers in neuroscience
2022

Collision of Two Tumors: A Case Report of a Lung Adenocarcinoma With Metastasis to a Pituitary Adenoma.

Journal of the ASEAN Federation of Endocrine Societies
2022

Risk Factors, Radiological and Clinical Outcomes in Subclinical and Clinical Pituitary Apoplexy.

Journal of clinical medicine
2022

Changes in Sinonasal and Overall Quality of Life Following Endoscopic Endonasal Surgery for Non-functioning Pituitary Adenomas: Results of A Prospective Observational Study.

Neurology India
2022

Sleep patterns in patients treated for non-secreting intra- and parasellar tumors: A self-report case-control study.

Frontiers in endocrinology
2023

Post-operative surveillance for somatotroph, lactotroph and non-functional pituitary adenomas after curative resection: a systematic review.

Pituitary
2022

Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma.

Journal of neuro-oncology
2023

Epigenomic and transcriptomic landscaping unraveled candidate repositioned therapeutics for non-functioning pituitary neuroendocrine tumors.

Journal of endocrinological investigation
2022

Impact of histopathological classification of non-functioning adenomas on long term outcomes: comparison of the 2004 and 2017 WHO classifications.

Pituitary
2022

Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?

Radiation oncology (London, England)
2022

DNA Methylation Profiling in Rare Sellar Tumors.

Biomedicines
2022

A Factorial Analysis on Visual Outcomes of Transsphenoidal Surgery for Pituitary Macroadenoma.

Asian journal of neurosurgery
2022

Expression pattern of non-coding RNAs in non-functioning pituitary adenoma.

Frontiers in oncology
2022

Endoscopic transsphenoidal surgery for non-functioning pituitary adenoma: Learning curve and surgical results in a prospective series during initial experience.

Frontiers in surgery
2022

Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis.

Pituitary
2022

A systematic review of molecular alterations in invasive non-functioning pituitary adenoma.

Endocrine
2022

Sevoflurane anesthesia rather than propofol anesthesia is associated with 3-month postoperative hypocortisolism in patients undergoing endoscopic transsphenoidal surgery for non-functional pituitary adenoma with preoperative normal hypothalamic-pituitary-adrenal axis.

Acta neurochirurgica
2022

Association between overweight and growth hormone secretion in patients with non-functioning pituitary tumors.

PloS one
2022

Discrimination between non-functioning pituitary adenomas and hypophysitis using machine learning methods based on magnetic resonance imaging‑derived texture features.

Pituitary
2022

Ectopic Cushing's syndrome from an ACTH-producing pheochromocytoma with a non-functioning pituitary adenoma.

Endocrinology, diabetes &amp; metabolism case reports
2022

Multivariable Diagnostic Prediction Model to Detect Hormone Secretion Profile From T2W MRI Radiomics with Artificial Neural Networks in Pituitary Adenomas.

Medeniyet medical journal
2022

Late onset of pituitary apoplexy following gonadotropin-releasing hormone agonist for prostate cancer treatment.

BMJ case reports
2022

Determinants of Short-Term Weight Gain Following Surgical Treatment for Craniopharyngioma in Adults.

Journal of Korean Neurosurgical Society
2022

Role of microRNAs in non-functioning pituitary adenoma.

JPMA. The Journal of the Pakistan Medical Association
2021

Metachronous Double Pituitary Adenoma with Altered Transcriptional Factor Profile: A Case Report and Literature Review.

NMC case report journal
2021

Hemostasis through Extended Transsphenoidal Route for Subarachnoid Hemorrhage after Conventional Transsphenoidal Surgery for a Pituitary Adenoma.

NMC case report journal
2022

Gamma knife radiosurgery in pituitary adenomas. A single-center experience.

Medicina
2021

An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.

Cancers
2021

A Novel Three-LncRNA Signature Predicting Tumor Recurrence in Nonfunctioning Pituitary Adenomas.

Frontiers in genetics
2021

Pseudocapsular resection in elderly patients with non-functioning pituitary adenoma.

Clinical neurology and neurosurgery
2021

Machine-Learning Prediction of Postoperative Pituitary Hormonal Outcomes in Nonfunctioning Pituitary Adenomas: A Multicenter Study.

Frontiers in endocrinology
2021

Baseline MRI findings as predictors of hypopituitarism in patients with non-functioning pituitary adenomas.

Endocrine connections
2021

Cardiovascular risk profile in growth hormone-treated adults with craniopharyngioma compared to non-functioning pituitary adenoma: a national cohort study.

European journal of endocrinology
2021

Isolated Neuropsychiatric Features with Non-functioning Pituitary Adenoma: Association or Coincidence?

Journal of pediatric neurosciences
2021

Pseudo-Cushing's state in a patient with non-functioning pituitary adenoma.

BMJ case reports
2021

Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy for Nonfunctioning Pituitary Adenoma.

Journal of neurological surgery. Part B, Skull base
2021

Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice.

Pituitary
2022

Predictive factors of postoperative diabetes insipidus in 333 patients undergoing transsphenoidal surgery for non-functioning pituitary adenoma.

Pituitary
2024

The open sella technique for surgical treatment of pituitary macroadenomas: Safety and efficacy in a large clinical series.

British journal of neurosurgery
2021

Giant Recurrence Pituitary Adenoma After Three Times Transphenoidal Removal Surgery, One Craniotomy Procedure, and 30 Doses of External Radiotherapy.

Acta medica Indonesiana
2021

Sphenoid sinus mucosal thickening in patients with non-functioning pituitary adenoma.

International journal of clinical practice
2021

Pituitary Hormonal Status after Endoscopic Endonasal Transphenoidal Removal of Nonfunctioning Pituitary Adenoma: 5 years' Experience in a Single Center.

Asian journal of neurosurgery
2021

Non-functioning pituitary adenomas and pregnancy: one-center experience and review of the literature.

Archives of endocrinology and metabolism
2021

Early hormonal recovery following endoscopic transsphenoidal surgery for silent non-functioning pituitary adenomas with hormone dysfunction.

Journal of neuro-oncology
2021

Screening and Identification of Key Microenvironment-Related Genes in Non-functioning Pituitary Adenoma.

Frontiers in genetics
2021

Rapid resolution of a third nerve palsy from pituitary apoplexy.

BMJ case reports
2021

Quality of Life and Sleep in Patients with Pituitary Adenoma in Relation to Tumor Type and Compression of the Optic Chiasm.

Journal of clinical medicine
2021

Role of pituitary stalk and gland radiological status on endocrine function and outcome after endoscopic transsphenoidal surgery for non-functioning pituitary adenomas.

Endocrine
2021

GH-induced LH hyporesponsiveness as a potential mechanism for hypogonadism in male patients with acromegaly.

Endocrine journal
2021

A comparative study of functioning and non-functioning pituitary adenomas.

Medicine
2021

Nomogram predictive model of post-operative recurrence in non-functioning pituitary adenoma.

Gland surgery
2021

Identifying critical protein-coding genes and long non-coding RNAs in non-functioning pituitary adenoma recurrence.

Oncology letters
2020

Clinical Parameters of Silent Corticotroph Adenomas With Positive and Negative Adrenocorticotropic Hormone Immunostaining: A Large Retrospective Single-Center Study of 105 Cases.

Frontiers in endocrinology
2021

Practice patterns in the management of recurrent and residual non-functioning pituitary adenomas: Results from a Canada-wide survey.

eNeurologicalSci
2020

Dome-Shaped Pituitary Enlargement in Primary Hypothyroidism: Avoiding Neurosurgical Interventions.

Journal of the ASEAN Federation of Endocrine Societies
2020

ESE audit on management of Adult Growth Hormone Deficiency in clinical practice.

European journal of endocrinology
2020

Pseudoacromegaly Associated with Non-Functioning Pituitary Adenoma.

European journal of case reports in internal medicine
2021

Chromosomal and oxidative DNA damage in non-functioning pituitary adenomas.

Endokrynologia Polska
2021

Cephalocaudal tumor diameter is a predictor of diabetes insipidus after endoscopic transsphenoidal surgery for non-functioning pituitary adenoma.

Pituitary
2021

Chiasmapexy for secondary empty sella syndrome: diagnostic and therapeutic considerations.

Pituitary
2020

Characteristics and clinical outcomes in pituitary incidentalomas and non-incidental pituitary tumors treated with endoscopic transsphenoidal surgery.

Medicine
2021

Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study.

Pituitary
2020

MRI radiomics for the prediction of recurrence in patients with clinically non-functioning pituitary macroadenomas.

Computers in biology and medicine
2020

The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a 68Ga -DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lan reotide on t umour size.

BMJ open
2020

Full Remission of Long-Term Premenstrual Dysphoric Disorder-Like Symptoms Following Resection of a Pituitary Adenoma: Case Report.

The American journal of case reports
2020

The quality of life after transnasal microsurgical and endoscopic resection of nonfunctioning pituitary adenoma.

Advances in clinical and experimental medicine : official organ Wroclaw Medical University
2020

Health-related quality of life in patients with non-functioning pituitary adenoma: a special focus on hydrocortisone replacement dose.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
2020

Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness.

Endocrine
2020

Current Status of Diagnosis and Management for Functioning Pituitary Tumors: Part I.

Neurology India
2020

Identification of a multidimensional transcriptome signature predicting tumor regrowth of clinically non‑functioning pituitary adenoma.

International journal of oncology
2020

Quality of care evaluation in non-functioning pituitary adenoma with chiasm compression: visual outcomes and timing of intervention clinical recommendations based on a systematic literature review and cohort study.

Pituitary
2019

NON-FUNCTIONAL PITUITARY TUMORS: A MISLEADING PRESENTATION OF AN INTRASELLAR PLASMACYTOMA.

Acta endocrinologica (Bucharest, Romania : 2005)
2020

The coexistence of recurrent pituitary adenoma and meningioma: case report.

Translational cancer research
2020

Comparative analysis of rhinologic outcomes in Cushing disease and non-functioning pituitary adenoma in patients submitted to endoscopic endonasal transsphenoidal surgery.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
2020

Content and system development of a digital patient-provider communication tool to support shared decision making in chronic health care: InvolveMe.

BMC medical informatics and decision making
2020

68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas.

European journal of hybrid imaging
2020

Integrated analysis of DNA methylation and mRNA expression profiles to identify key genes involved in the regrowth of clinically non-functioning pituitary adenoma.

Aging
2020

Cut-off values for sufficient cortisol response to low dose Short Synacthen Test after surgery for non-functioning pituitary adenoma.

Acta neurochirurgica
2021

Giant Non-Functioning Pituitary Adenoma: Clinical Characteristics and Therapeutic Outcomes.

Experimental and clinical endocrinology &amp; diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
2019

Identification of key genes in invasive clinically non-functioning pituitary adenoma by integrating analysis of DNA methylation and mRNA expression profiles.

Journal of translational medicine
2020

Preoperative growth hormone (GH) peak values during a GH releasing peptide-2 test reflect the severity of hypopituitarism and the postoperative recovery of GH secretion in patients with non-functioning pituitary adenomas.

Endocrine journal
2020

Multimodal therapy in aggressive pituitary tumors.

Endocrinologia, diabetes y nutricion
2019

Postoperative expression of Cushing disease in a young male: metamorphosis of silent corticotroph adenoma?

Endocrinology, diabetes &amp; metabolism case reports
2019

Identification of CDK6 and RHOU in Serum Exosome as Biomarkers for the Invasiveness of Non-functioning Pituitary Adenoma.

Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
2019

Cavernous sinus haemangioma with intrasellar extension mimicking non-functioning pituitary adenoma - A case report and review of literature.

Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
2019

The burden of disease for pituitary patients.

Best practice &amp; research. Clinical endocrinology &amp; metabolism
2019

Significance of Elevated HMGB1 Expression in Pituitary Apoplexy.

Anticancer research
2019

Endocrinological Outcome of Endoscopic Transsphenoidal Surgery for Functioning and Non-Functioning Pituitary Adenoma.

The Malaysian journal of medical sciences : MJMS
2023

Unexpected concomitant pituitary adenoma and suprasellar meningioma: a case report and review of the literature.

British journal of neurosurgery
2019

The pre- and postoperative illness trajectory in patients with pituitary tumours.

Endocrine connections
2019

Predicting the regrowth of clinically non-functioning pituitary adenoma with a statistical model.

Journal of translational medicine
2019

Non-functioning pituitary macroadenoma: surgical outcomes, tumor regrowth, and alterations in pituitary function-3-year experience from the Iranian Pituitary Tumor Registry.

Hormones (Athens, Greece)
2019

Identification of Important Invasion-Related Genes in Non-functional Pituitary Adenomas.

Journal of molecular neuroscience : MN
2019

Quality of Life but not Cognition is Impacted by Radiotherapy in Patients with Non-Functioning Pituitary Adenoma.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2019

Endocrinological Outcomes of Intraoperative MRI-Guided Endoscopic Transsphenoidal Surgery for Non-Functioning Pituitary Adenoma.

Turkish neurosurgery
2019

Incidence rate and risk factors of early repolarization in patients with growth hormone-secreting pituitary adenoma: a cohort study.

Therapeutics and clinical risk management
2019

Association of PTTG1 polymorphism rs1895320, rs2910200 and rs6882742 with non-functioning pituitary adenomas in Chinese Han population: a case-control study.

Metabolic brain disease
2018

Recurrence in silent corticotroph adenomas after primary treatment: A systematic review and meta-analysis.

The Journal of clinical endocrinology and metabolism
2019

A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma.

Oncology reports
2019

Genome-wide identification of lncRNAs and mRNAs differentially expressed in non-functioning pituitary adenoma and construction of an lncRNA-mRNA co-expression network.

Biology open
2023

Spindle cell oncocytoma of the neurohypophysis with metastasis to the sphenoparietal sinus and immunohistochemical negativity for S100 and epithelial membrane antigen (EMA).

British journal of neurosurgery
2019

Autoimmune thyroid diseases are more common in patients with prolactinomas: a retrospective case-control study in an Italian cohort.

Journal of endocrinological investigation
2018

Comorbidities in patients with non-functioning pituitary adenoma: influence of long-term growth hormone replacement.

European journal of endocrinology
2018

FGFR2 gene polymorphism rs2981582 is associated with non-functioning pituitary adenomas in Chinese Han population: a case-control study.

Bioscience reports
2018

Spectrum of Pituitary disorders: A retrospective study from Basrah, Iraq.

F1000Research
2018

Postoperative growth hormone dynamics in clinically nonfunctioning pituitary adenoma.

Endocrine journal
2018

Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.

Endocrine
2018

Data of phosphoproteomic analysis of non-functioning pituitary adenoma.

Data in brief
2018

Clinical and epidemiological characteristics of pituitary tumours in a single centre in Saudi Arabia.

Hormones (Athens, Greece)
2018

Interpretation of Serum Gonadotropin Levels in Hyperprolactinaemia.

Neuroendocrinology
2018

Recurrent non-functioning pituitary adenomas: a review on the new pathological classification, management guidelines and treatment options.

Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
2018

Non-invasive radiomics approach potentially predicts non-functioning pituitary adenomas subtypes before surgery.

European radiology
2018

Effects of active acromegaly on bone mRNA and microRNA expression patterns.

European journal of endocrinology
2018

Mortality in patients with non-functioning pituitary adenoma.

Pituitary
2018

Management of NFAs: medical treatment.

Pituitary
2018

Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?

Journal of neuro-oncology
2018

How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review.

Pituitary
2017

A novel "total pituitary hormone index" as an indicator of postoperative pituitary function in patients undergoing resection of pituitary adenomas.

Oncotarget
2019

Limitations of high throughput methods for miRNA expression profiles in non-functioning pituitary adenomas.

Pathology oncology research : POR
2017

Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas.

Endocrine pathology
2017

Amelanotic melanocytoma of the sella mimicking pituitary adenoma.

Clinical neuropathology
2017

Prevalence, Clinical Features, and Natural History of Incidental Clinically Non-Functioning Pituitary Adenomas.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2017

All that glitters on PET is not cancer! 18F-deoxy-glucose avidity versus tumor biology: pituitary incidentaloma in a survivor of two previous unrelated malignancies.

Endokrynologia Polska
2017

In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism.

European journal of endocrinology
2017

Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma.

European journal of endocrinology
2017

Early postoperative growth in non-functioning pituitary adenomas; A tool to tailor safe follow-up.

Endocrine
2017

The impact on cognitive functions of patients with pituitary adenoma before and after surgery.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2017

Non-functioning pituitary adenoma underwent surgery: A multicenter retrospective study over the last four decades (1977-2015).

European journal of internal medicine
2017

Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile.

Biochemical genetics
2017

Pituitary Carcinoma in a Patient with an SDHB Mutation.

Endocrine pathology
2017

Incidence of malignant tumours in patients with a non-functioning pituitary adenoma.

Endocrine-related cancer

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Adenoma hipofisário não-secretor.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Adenoma hipofisário não-secretor

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Oridonin regulates pituitary-derived folliculostellate cells apoptosis via the p38 MAPK/p53 signalling pathway.
    European journal of pharmacology· 2026· PMID 41724459mais citado
  2. Sex-related differences in healthcare utilization and costs among patients with pituitary adenomas.
    Pituitary· 2026· PMID 41653359mais citado
  3. Sex and Age Differences in Transcription Factor and Hormonal Immunostaining in Patients With Nonfunctioning Pituitary Adenomas.
    Operative neurosurgery (Hagerstown, Md.)· 2026· PMID 41537647mais citado
  4. Clinicopathological features and outcomes in non-functioning pituitary neuroendocrine tumors: a transcription factor-driven subtype analysis.
    Journal of neuro-oncology· 2026· PMID 41504789mais citado
  5. Impact of sex on mortality in patients with pituitary adenomas.
    Pituitary· 2026· PMID 41644768mais citado
  6. Hypogonadotropic Hypogonadism Before and After Transsphenoidal Surgery for Non-Functioning Pituitary Adenoma.
    Clin Endocrinol (Oxf)· 2026· PMID 41940466recente
  7. The impact of a non-functioning pituitary adenoma on life - A qualitative study of patients' experiences.
    PLoS One· 2026· PMID 41915654recente
  8. Natural history of non-functioning pituitary neuroendocrine tumours: impact of baseline characteristics and gender-specific clinical presentations.
    Pituitary· 2026· PMID 41894082recente
  9. Risk factors for pituitary apoplexy: a meta-analysis and development of a clinical prediction nomogram.
    Front Neurol· 2026· PMID 41884344recente
  10. Integrated proteomic and metabolomic profiling reveals molecular signatures underlying invasiveness in non-functioning pituitary adenomas.
    Oncol Lett· 2026· PMID 41867419recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:91349(Orphanet)
  2. MONDO:0019613(MONDO)
  3. GARD:19159(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q18556965(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Adenoma hipofisário não-secretor
Compêndio · Raras BR

Adenoma hipofisário não-secretor

ORPHA:91349 · MONDO:0019613
Prevalência
1-5 / 10 000
Herança
Not applicable
CID-10
D35.2 · Neoplasia benigna da glândula hipófise (pituitária)
CID-11
Ensaios
3 ativos
Início
Adolescent, Adult, Childhood
Prevalência
0.0 (Europe)
MedGen
UMLS
C0338078
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades